

## Harry's Head

Stanley Wine, MD, FRCPC

### Meet Harry

- He is a 20-year-old male who noted a white patch of hair on his scalp six months ago
- He has had a palpable lesion in that area for years

### Physical Examination

- There is a visible localized area of gray hair surrounding a speckled, pink nevus



### What is your diagnosis?

- |               |                              |                      |
|---------------|------------------------------|----------------------|
| a) Vitiligo   | c) Resolving alopecia areata | e) Familial poliosis |
| b) Halo nevus | d) Melanoma                  |                      |

Send in your correct answer for a chance to win a **CME** courier pack!

*Win*



Fill in the information below and **fax this page to:**

**1 (888) 695-8554**

If you diagnose correctly, you will be entered in our monthly draw.

Please circle the letter you believe corresponds to the correct answer.

Your Answer:   **a**   **b**   **c**   **d**   **e**

Name: \_\_\_\_\_

Address: \_\_\_\_\_

Tel: \_\_\_\_\_

E-mail: \_\_\_\_\_

Or e-mail the answer to **cme@sta.ca** and include "CME courier pack" in the subject line. Also, include your NAME, ADDRESS and PHONE NUMBER.

See page 4 for the answer to last month's case 



## Here is the answer to last month's case

### Meet Francine

- Francine is a 34-year-old Asian female with a several month history of a slowly enlarging firm plaque on her back
- The lesion is occasionally pruritic and feels dry and wrinkly to the touch
- Francine has no personal or family history of skin problems
- Francine has hypothyroidism for which she is on medication and is otherwise healthy with no drug allergies



### What is your diagnosis?

- a) Sclerodema
- b) Sclerotic basal cell carcinoma
- c) Morphea
- d) Lipodermatosclerosis
- e) Stiff skin syndrome

### Answer: C

Morphea (**answer c**) is a localized scleroderma due to deposition of excessive collagen with resulting thickening of dermal and/or subcutaneous tissues. There are several subtypes, including focal plaque, linear, generalized, and deep morphea; none of these have systemic features of systemic sclerosis.

Most patients (70%) with morphea present with plaque-type morphea, with generalized, linear, and deep variants each making up 10% of cases. As much as half of morphea cases occur in the pediatric population where linear morphea (66%) is the most common type, followed by plaque-type (25%).

Morphea has a benign, self-limited course in most cases with no effect on mortality. Linear and deep morphea can cause considerable morbidity, especially in children where growth may be affected.

Plaque-type morphea is the most common subtype. It is benign, with variants. It predominantly affects the dermis; although, the epidermis

is occasionally affected with lichen sclerosus et atrophicus. Morphea lesions are round or oval (in a horizontal direction), indurated plaques from 1 to 20 cm in diameter, and they often begin as erythematous to violaceous patches.

The trunk is most commonly affected, and the face is typically spared. As the lesion expands, sclerosis develops centrally; the surface becomes smooth, shiny and ivory-waxy, and the lesion losses adnexal structures (hair, sweat glands). The margins are typically surrounded by a violaceous zone or telangiectasias.

Although the diagnosis is typically clinical, a biopsy can be useful for confirmation. A deep punch or incisional biopsy including subcutaneous fat is sufficient. Radiography is of benefit for linear or deep morphea if underlying bone involvement is suspected. MRI of the brain and/or EEG may be useful for craniofacial involvement.

Treatment is aimed at reducing the inflammatory activity of the early stages of the disease; treatment of late sclerotic disease is less successful. The natural history of plaque-type morphea involves spontaneous resolution after a few years, and thus, lesions are treated with potent topical or intralesional steroids to halt disease progression and minimize inflammation.

Individuals with deeper, generalized, linear morphea require referral to a dermatologist for consideration of systemic steroids or methotrexate. Phototherapy is another useful option, particularly with the deeper penetrating UVA wavelengths.

*cme*

**Benjamin Barankin, MD, FRCPC**

### Congratulations

to our winner for the months of  
September 2011!

**Dr. Mark Wylie**

Medicine Hat, Alberta